Lung
Broncheoalveolar Carcinoma (BAC):
IRB #H-26769/SWOG #S0635 : A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC Features
SCLC – Limited Stage:
CIRB #2008-033C/CTSU #C30610-R0538: Phase III Comparison Of Thoracic Radiotherapy Regimens In Patients With Limited Small Cell Lung Cancer also Receiving Cisplatin And Etoposide
SCLC – Extensive Stage:
IRB #H-28706/SWOG #S0802: A Randomized Phase II Trial of Weekly Topotecan with and without AVE0005 (Aflibercept; NSC-724770) in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC) (pending)
NSCLC – Never-Smokers:
IRB #H-26781/SWOG #S0636 : A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Never-Smokers with Stage IIIB and IV Primary NSCLC Adenocarcinomas
NSCLC – less than 3cm:
IRB #2007-039C/CTSU #C140503: A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (less than or equal to 2 cm) Peripheral Non-Small Cell Lung Cancer
IRB #2005-037C/ACOSOG #Z4032: A Randomized Phase III Study of Sublobar Resection vs Sublobar Resection Plus Brachytherapy in High Risk Patients with Non-Small Cell Lung Cancer (NSCLC), 3 cm or Smaller
IRB #H-26112/ACOSOG #Z4033: A Pilot Study of Radiofrequency Ablation in High-Risk Patients with Stage Ia Non-Small Cell Lung Cancer
NSCLC – Adjuvant:
GSK MAGRIT/WIRB #20070652 : MAGE-A3 as Adjuvant Non-Small Cell Lung Cancer Immunotherapy (Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with Non-Small Cell Lung Cancer
IRB #2007-040C/SWOG #E1505: Phase III Randomized, Adjuvant Chemotherapy with or without Avastin in Completely Resected Stage IB (greater than or equal to 4 cm)-IIIA Non-Small Cell Lung Cancer
CTSU #C30506/IRB #2009-034C: A Randomized, Phase III Trial of Adjuvant Therapy in Early Stage Non-Small Cell Lung Cancer Evaluating the Potential Utility of a Genomic Prognostic Model to Identify Patients as Candidates for Adjuvant Chemotherapy
NSCLC – Locally Advanced:
IRB #H-26701: Feasibility and Outcome of CyberKnife Precision Hypofractionated Radiosurgery for Curative Management of Non-Small Cell Lung Cancer
NSCLC – Locally Advanced/Metastatic:
Amgen 20050201 / WIRB #20070717: A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer
RTOG #R0972/C30605/ IRB #H-28756: A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-Small Cell Lung Cancer (pending)
NSCLC – Ancillary:
Seimen’s/WIRB #2009-0147: : A Phase II/III, Open Label, Non-Randomized, Multi – Center Study Of Positron Emission Tomography (PET) Imaging with [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation
ACRIN #6678/IRB #H-28245: FDG-PET/CT as a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in Non-Small Cell Lung Cancer
IRB #H-25305/SWOG #S0424: Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men (Smoking stratum closed)
IRB #H-23981/SWOG #S9925: Lung Cancer Specimen Repository Protocol, Ancillary
IRB #H-28464: Health Behaviors Among Adults with Lung Cancer and Their Family Members
